Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 94.0%

Neg 0% Neu 0% Pos 94%

Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform and raises the price target from $12 to $25.